Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinibwith diffuse leptomeningeal carcinomatosis

Oncologist

Volumn 20, Issue 2, 2015, Pages 224-226

  Ignatius Ou, Sai Hong ^a   Sommers, Karen R ^a   Azada, Michele C ^a   Garon, Edward B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DEXAMETHASONE; DOCETAXEL; FLUCONAZOLE; NAVELBINE; PACLITAXEL; PEMETREXED; ACTIVIN RECEPTOR 2; ACVRL1 PROTEIN, HUMAN; CARBAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADENOCARCINOMA; ADULT; ARTICLE; BONE METASTASIS; BRAIN RADIATION; BRAIN TUMOR; CANCER RECURRENCE; CARCINOMATOUS MENINGITIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIPLOPIA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DYSARTHRIA; FACIAL NUMBNESS; FEMALE; FLUID RETENTION; FOLLOW UP; HAND PARESTHESIA; HUMAN; INSOMNIA; LUMBAR PUNCTURE; MALIGNANT PLEURA EFFUSION; MEDICAL PROCEDURES; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD METASTASIS; THORACIC SPINE RADIATION; THRUSH; TREATMENT RESPONSE; VAGINA CANDIDIASIS; WEIGHT GAIN; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CEREBELLUM; GENETICS; MENINGEAL CARCINOMATOSIS; PATHOLOGY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACTIVIN RECEPTORS, TYPE II; ADULT; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CEREBELLUM; FEMALE; HUMANS; MENINGEAL CARCINOMATOSIS; NEOPLASM STAGING; PIPERIDINES; PYRAZOLES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84922741549     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0309     Document Type: Article

References (16)

1. Solomon BJ, Mok T, Kim DW et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Eng JMed 2014;371:2167-2177.
2. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl JMed 2013;368:2385-2394.
3. Gainor JF, Ou SH, Logan J et al. The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol 2013;8: 1570-1573.
4. Seto T, Kiura K, Nishio M et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-arm, open-label, phase 1-2 study. Lancet Oncol 2013;14: 590-598.
5. Gadgeel SM, Gandhi L, Riely GJ et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinibresistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014;15: 1119-1128.
6. Gainor JF, Sherman AS, Willoughby K et al. Alectinib salvages CNS metastases in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 2014 [Epub ahead of print].
7. Costa DB, Kobayashi S, Pandya SS et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011;29: e443-e445.
8. Ou SHI, Jänne PA, Bartlett CH et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014;25:415-422.
9. Ahn HK, Han B, Lee SJ et al. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis. Lung Cancer 2012;76:253-254.
10. Arrondeau J, Ammari S, Besse B et al. LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-small-cell lung cancer. J Thorac Oncol 2014;9:e62-e63.
11. Gettinger SN, Bazhenova L, Salgia R et al. Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK1non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(suppl): 8047a.
12. Gandhi L, Drappatz J, Ramaiya NH et al. High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer. J Thorac Oncol 2013; 8:e3-e5.
13. Peled N, Zach L, Liran O et al. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer. J Thorac Oncol 2013;8:e112-e113.
14. Kim YH, Ozasa H, Nagai H et al. High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J Thorac Oncol 2013;8:e85-e86.
15. Lee SJ, Lee JI, Nam DH et al. Leptomeningeal carcinomatosis in nonsmall- cell lung cancer patients: Impact on survival and correlated prognostic factors. J Thorac Oncol 2013;8:185-191.
16. Awad MM, Shaw AT. ALK inhibitors in non-small cell lung cancer: Crizotinib and beyond. Clin Adv Hematol Oncol 2014;12:429-439.